Enveric Seeks Reverse Split, Massive Share Increase to Boost Stock, Funding

TL;DR

**ENVB is desperate to fix its stock price and raise cash, pushing a reverse split and a massive share authorization that screams dilution.**

AI Summary

Enveric Biosciences, Inc. (ENVB) is holding a Special Meeting on December 11, 2025, to address critical financial and operational challenges. The company seeks stockholder approval for the issuance of shares underlying warrants from Inducement Letters dated September 17, 2025, and an Engagement Letter dated December 8, 2024, which could exceed 20% of outstanding Common Stock, as required by Nasdaq Listing Rule 5635(d). This warrant inducement transaction, closed on September 18, 2025, generated approximately $2.2 million in gross cash proceeds. Additionally, ENVB proposes a reverse stock split at a ratio between 1-for-5 and 1-for-15 to boost its stock price, which closed at $0.62 on October 22, 2025, and increase investor appeal. The company also seeks to amend its Charter to increase authorized Common Stock from 100,000,000 to 5,000,000,000 shares to provide flexibility for future financing and strategic transactions. Failure to approve the Issuance Proposal means warrant holders cannot exercise, and ENVB must call subsequent meetings every 90 days.

Why It Matters

This DEF 14A filing is crucial for Enveric Biosciences as it directly addresses the company's ability to raise capital and maintain its Nasdaq listing. The proposed reverse stock split aims to increase the per-share price from $0.62, potentially attracting institutional investors and improving liquidity, which is vital for a small-cap biotech. The significant increase in authorized shares from 100 million to 5 billion signals a potential for substantial future dilution but also provides the Board with flexibility for strategic financing, mergers, or acquisitions. For investors, these proposals represent a high-stakes vote on the company's financial stability and future growth trajectory in a competitive biotech landscape.

Risk Assessment

Risk Level: high — The risk level is high due to the company's reliance on stockholder approval for warrant exercises that generated $2.2 million in gross cash proceeds. Failure to approve the Issuance Proposal means these funds are inaccessible, and the company must call meetings every 90 days. The proposed increase in authorized shares from 100,000,000 to 5,000,000,000 shares, combined with a potential reverse stock split, indicates significant future dilution risk for existing stockholders.

Analyst Insight

Investors should carefully evaluate the potential for significant dilution from the proposed increase in authorized shares and the implications of the reverse stock split on market capitalization versus share price. Consider voting 'FOR' the Issuance Proposal to unlock the $2.2 million in cash proceeds, but weigh the long-term impact of the Authorized Stock Increase Proposal on your ownership percentage.

Key Numbers

• $2.2M — Gross cash proceeds (From warrant inducement transaction, contingent on stockholder approval)
• $0.62 — Common Stock closing price (As of October 22, 2025, driving reverse stock split proposal)
• 1-for-5 to 1-for-15 — Reverse stock split ratio range (Proposed to increase per-share price)
• 100M to 5B — Authorized Common Stock increase (Proposed to provide flexibility for future financing)
• 20% — Nasdaq Listing Rule threshold (Issuance of shares exceeding this requires stockholder approval)
• 6,219,568 — Shares of Common Stock outstanding (As of the Record Date, October 13, 2025)
• 90 days — Frequency of required meetings (If Issuance Proposal is not approved)
• $12,500 — Proxy solicitor fee (Paid to Kingsdale Advisors)

Key Players & Entities

• Enveric Biosciences, Inc. (company) — Registrant
• Joseph Tucker (person) — Chief Executive Officer and Proxy
• Kevin Coveney (person) — Chief Financial Officer and Proxy
• Nasdaq Listing Rule 5635(d) (regulator) — Rule requiring stockholder approval for certain issuances
• H.C. Wainwright & Co., LLC (company) — Placement Agent
• Kingsdale Advisors (company) — Proxy solicitor
• $2.2 million (dollar_amount) — Gross cash proceeds from warrant inducement transaction
• $0.62 (dollar_amount) — Closing price of Common Stock on October 22, 2025
• October 13, 2025 (date) — Record date for Special Meeting
• December 11, 2025 (date) — Date of Special Meeting

FAQ

Risk Factors

• Nasdaq Listing Rule Compliance [high — regulatory]: The company seeks stockholder approval to issue shares underlying warrants that could exceed 20% of outstanding Common Stock. Failure to obtain this approval, as required by Nasdaq Listing Rule 5635(d), would prevent warrant exercise and necessitate recurring 90-day meetings.
• Reverse Stock Split Necessity [medium — financial]: Enveric's Common Stock closed at $0.62 on October 22, 2025, prompting a proposed reverse stock split with a ratio between 1-for-5 and 1-for-15. This is intended to increase the per-share price and enhance investor appeal.
• Authorized Share Increase for Future Needs [medium — financial]: The company proposes to increase authorized Common Stock from 100,000,000 to 5,000,000,000 shares. This significant increase aims to provide future flexibility for financing and strategic transactions, but dilutes existing shareholders.
• Dependence on Warrant Inducement Proceeds [high — financial]: The warrant inducement transaction, contingent on stockholder approval, generated approximately $2.2 million in gross cash proceeds. The company's financial stability may be significantly reliant on these funds.

Industry Context

Enveric Biosciences operates in the biotechnology sector, which is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. The industry is highly competitive, with companies vying for funding and market share. Recent trends include a focus on novel therapeutic areas and the increasing importance of strategic partnerships and financing rounds to sustain operations.

Regulatory Implications

The company faces significant regulatory scrutiny, particularly concerning Nasdaq listing rules. Failure to secure stockholder approval for the warrant issuance could lead to delisting or continued compliance challenges. The proposed reverse stock split and increase in authorized shares are also subject to corporate governance and exchange regulations.

What Investors Should Do

1. Vote FOR the Issuance Proposal
2. Vote FOR the Reverse Stock Split Proposal
3. Vote FOR the Increase in Authorized Common Stock Proposal

Key Dates

• 2025-12-11: Special Meeting of Stockholders — Stockholders will vote on critical proposals including warrant issuance approval and a reverse stock split, which are vital for the company's financial and operational future.
• 2025-10-22: Common Stock Closing Price — The stock closed at $0.62, highlighting the need for a reverse stock split to improve its market perception and meet potential listing requirements.
• 2025-10-13: Record Date — Established the list of stockholders entitled to vote at the Special Meeting.
• 2025-09-17: Inducement Letters Dated — These letters are the basis for the warrant issuance that requires stockholder approval.
• 2024-12-08: Engagement Letter Dated — This letter is also related to the warrant issuance requiring stockholder approval.
• 2025-09-18: Warrant Inducement Transaction Closed — This transaction, which generated $2.2 million in gross proceeds, is contingent on stockholder approval for the underlying share issuance.

Glossary

DEF 14A

A proxy statement filing required by the SEC for annual or special meetings of shareholders, containing detailed information about matters to be voted upon. (This document outlines the critical proposals Enveric Biosciences' shareholders will vote on, including financial restructuring and share issuances.)

Warrants

Securities that give the holder the right, but not the obligation, to purchase a company's stock at a predetermined price within a specified timeframe. (The company is seeking approval to issue shares underlying warrants from inducement letters, which is a key proposal at the Special Meeting.)

Inducement Letters

Agreements used to incentivize investors or parties to enter into transactions, often involving the issuance of securities. (These letters are the source of the warrants that require stockholder approval for share issuance, tied to a $2.2 million cash raise.)

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (Enveric is proposing a reverse stock split to increase its stock price from $0.62 per share, aiming to improve investor appeal and potentially meet exchange listing requirements.)

Authorized Common Stock

The maximum number of shares of common stock that a corporation is legally permitted to issue, as specified in its charter. (Enveric seeks to increase its authorized shares from 100 million to 5 billion to provide flexibility for future financing and strategic actions.)

Nasdaq Listing Rule 5635(d)

A rule requiring shareholder approval for the issuance of securities in connection with certain acquisitions or in private placements if the number of shares issued exceeds 20% of the outstanding common stock. (This rule necessitates Enveric's request for stockholder approval for the warrant share issuance, as it could exceed the 20% threshold.)

Year-Over-Year Comparison

This DEF 14A filing indicates a critical juncture for Enveric Biosciences, focusing on immediate financial needs and strategic restructuring. Unlike previous filings that might have detailed ongoing clinical trials or R&D progress, this document is heavily weighted towards proposals necessary for continued operation and compliance, such as warrant issuances and stock splits, driven by a low stock price of $0.62 as of October 22, 2025.

Key Financial Figures

• $0.01 — f shares of our common stock, par value $0.01 per share (“Common Stock”),
• $12,500 — he solicitation of proxies for a fee of $12,500, plus reimbursement of expenses. In add
• $2.2 m — in gross cash proceeds of approximately $2.2 million, before deducting placement agent
• $0.62 — ast 12 months with its closing price at $0.62 as of October 22, 2025. At its current

Filing Documents

• formdef14a.htm (DEF 14A) — 308KB
• proxy_001.jpg (GRAPHIC) — 399KB
• proxy_002.jpg (GRAPHIC) — 321KB
• 0001493152-25-019750.txt ( ) — 1300KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 20 OTHER MATTERS 21 DEADLINE FOR RECEIPT OF STOCKHOLDER PROPOSALS 21 STOCKHOLDERS SHARING THE SAME ADDRESS 21 Annex A – Certificate of Amendment to Amended and Restated Certificate of Incorporation (Reverse Stock Split) A-1 Annex B – Certificate of Amendment to Amended and Restated Certificate of Incorporation (Increase in Authorized Stock) B-1 -i- ENVERIC BIOSCIENCES, INC. 245 First Street, Riverview II, 18th Floor Cambridge, MA 02142 PROXY FOR SPECIAL MEETING OF STOCKHOLDERS To Be Held on December 11, 2025 Unless the context otherwise requires, references in this proxy statement to “we,” “us,” “our,” the “Company” or “Enveric” refer to Enveric Biosciences, Inc., a Delaware corporation and its consolidated subsidiary as a whole. In addition, unless the context otherwise requires, references to “stockholders” are to the holders of our common stock, par value $0.01 per share (“Common Stock”). The accompanying proxy is solicited by the Board of Directors (the “Board”) on behalf of Enveric Biosciences, Inc. to be voted at our Special Meeting of Stockholders (the “Special Meeting”) to be held on December 11, 2025, and at any adjournment, continuation or postponement thereof, for the purposes set forth in the accompanying Notice of Special Meeting of Stockholders (the “Notice”). The Special Meeting will be held virtually via a live webcast on the Internet on www.virtualshareholdermeeting.com/ENVB2025SM at 10:00 a.m. Eastern time. This proxy statement and accompanying form of proxy are dated October 27, 2025 and are expected to be first sent or given to stockholders on or about October 27, 2025. Our executive offices are located at, and our mailing address is, 245 First Street, Riverview II, 18th Floor, Cambridge, MA 02142. We will

View Full Filing

View this DEF 14A filing on SEC EDGAR